Eli Lilly to Acquire FDA-Approved Nexus Facility, Production to Begin End of 2025

• Eli Lilly and Company and Nexus Pharmaceuticals, LLC have announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus.

Eli Lilly and Company (NYSE: LLY) and Nexus Pharmaceuticals, LLC have announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a leading sterile manufacturer in the pharmaceutical industry. This acquisition, announced on April 22, 2024, will take place in Pleasant Prairie, Wisconsin.

The acquisition of this FDA-approved facility will further expand Lilly’s global parenteral (injectable) product manufacturing network and support increased demand for the company’s medicines. Lilly estimates that production at this facility could begin at the end of 2025, marking a significant expansion in their manufacturing capabilities.

Edgardo Hernandez, executive vice president and president, Lilly manufacturing, expressed his enthusiasm about the acquisition, stating, “The acquisition of this state-of-the-art facility underscores our unwavering commitment to growth and innovation, and we look forward to welcoming talented new Nexus colleagues to Lilly from the Pleasant Prairie facility. We are investing boldly to serve our patients, to meet product demand and to build capabilities for our robust pipeline of the future.”

Usman Ahmed, president and chief executive officer of Nexus, also shared his excitement about the acquisition. He said, “We are excited Lilly is continuing our family’s mission of providing lifesaving medications to those who need them most. This milestone is a testament to the dedication of our Nexus employees in building a best-in-class injectable manufacturing facility. The combination of our teams and infrastructure with Lilly’s global platform will benefit patients all over the world.”